Risk of Systemic Adverse Events Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice
Ophthalmology in press（preproof）
https://doi.org/10.1016/j.ophtha.2020.07.062
(2019 年Retina Society Annual Meeting データ)
ベバシズマブ、ラニビズマブ、アフリベルセプト間でSAE は変わらず
昨年、抗VEGF 硝子体注射でSAE リスクは変わらない、原病による可能性指摘
DOI: 10.1016/j.ophtha.2018.09.040
87,844 patients received initial anti-VEGF injections for nAMD, DRD, and RVO
between 1/1/2007 and 6/30/2018
(69,007 bevacizumab; 10,895 ranibizumab; 7,942 aflibercept) （THY)